<DOC>
	<DOCNO>NCT01487863</DOCNO>
	<brief_summary>The purpose study evaluate impact concurrent versus sequential administration abiraterone acetate plus prednisone product parameter sipuleucel-T , assess safety efficacy sipuleucel-T concurrent sequential administration abiraterone acetate plus prednisone men metastatic castrate resistant prostate cancer .</brief_summary>
	<brief_title>Concurrent Versus Sequential Treatment With Sipuleucel-T Abiraterone Men With Metastatic Castrate Resistant Prostate Cancer ( mCRPC )</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>historically document prostate cancer confirm pathology report prostate biopsy radical prostatectomy specimen metastatic status evidence image obtain &lt; /= 56 day prior registration demonstrate bone metastasis lymph node metastasis castrate resistant prostate cancer : castrate level testosterone ( &lt; /= 50 ng/dL ; evidence disease progression concomitant surgical medical castration serum PSA &gt; /= 2.0 ng/mL castrate level testosterone ( &lt; /= 50 ng/dL ) achieve via medical surgical castration baseline ECOG performance status &lt; /= 1 systolic blood pressure ( BP ) &lt; /= 140 mm HG diastolic BP &lt; /= 90 mm Hg screen adequate baseline hematologic , renal , liver function must live permanent residence within comfortable drive distance ( roundtrip within one day ) clinical trial site presence know lung , liver , brain metastasis , malignant pleural effusion , malignant ascites New York Heart Association Class III IV heart failure medical condition may compromise increase blood pressure , hypokalemia , fluid retention ChildPugh Class B C hepatic insufficiency spinal cord compression , imminent long bone fracture , condition likely require radiation therapy and/or steroid pain control know adrenalcortical insufficiency medical contraindication receive prednisone prior treatment sipuleucelT previous treatment abiraterone acetate ( Zytiga ( R ) ) ipilimumab ( Yervoy ( TM ) ) requirement systemic immunosuppressive therapy reason . Use inhale , intranasal , intraarticular , topical steroid allow . treatment investigational vaccine immunotherapy history stage III great cancer , exclude prostate cancer . Basal squamous cell skin cancer must adequately treated subject must diseasefree time registration . Subjects history stage I II cancer must adequately treated diseasefree ≥ 3 year time registration . myocardial infarction ventricular atrial arrhythmia within 6 month prior registration ongoing antiandrogen withdrawal response . systemic steroid use within ≤ 60 day registration treatment denosumab ( Xgeva ( R ) Prolia ( R ) ) within ≤ 3 month prior registration positive test HIV HTLV infection . Subjects positive test hepatitis B hepatitis C allow provide meet LFT criterion sign acute infection active disease . treatment follow medication intervention within 28 day prior registration : external beam radiation major surgery require general anesthetic ; saw palmetto ; megestrol acetate ( Megace ( R ) ) , diethylstilbestrol , cyproterone ; 5alphareductase inhibitor ( e.g . finasteride [ Proscar ( R ) ] , dutasteride [ Avodart ( R ) ] ) ; steroidal antiandrogen therapy ; systemic therapy prostate cancer , except medical castration ; treatment investigational product prostate cancer ; substrates CYP2D6 ( e.g . include limited thioridazine ) ; inhibitor CYP3A4 ( e.g . include limited ketoconazole , itraconazole , clarithromycin , nefazodone , telithromycin , voriconazole ) ; inducer CYP3A4 ( e.g . include limited phenytoin , carbamazepine , rifampin , rifapentine , phenobarbital ) requirement treatment opioid analgesic within 21 day prior registration active infection infection require parenteral antibiotic therapy cause fever within 7 day registration medical intervention , condition , circumstance , opinion Investigator Dendreon Medical Monitor , could compromise adherence study requirement otherwise compromise study 's objective</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>prostate</keyword>
	<keyword>AIPC</keyword>
	<keyword>androgen-independent</keyword>
	<keyword>androgen independent</keyword>
	<keyword>hormone insensitive</keyword>
	<keyword>hormone-insensitive</keyword>
	<keyword>PSA</keyword>
	<keyword>prostatic adenocarcinoma</keyword>
	<keyword>hormone-refractory</keyword>
	<keyword>hormone refractory</keyword>
	<keyword>HRPC</keyword>
	<keyword>immune therapy</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>vaccine</keyword>
	<keyword>dendritic cell</keyword>
	<keyword>antigen-presenting cell</keyword>
	<keyword>antigen present cell</keyword>
	<keyword>cancer vaccine</keyword>
	<keyword>therapeutic vaccine</keyword>
	<keyword>therapeutic cancer vaccine</keyword>
	<keyword>recombinant</keyword>
	<keyword>biological</keyword>
	<keyword>biopharmaceutical</keyword>
	<keyword>biotechnology</keyword>
	<keyword>biotech</keyword>
</DOC>